UCB : Bimekizumab on the right track
>Bimekizumab: positive recommendation from CHMP in psoriasis - UCB’s share price gained +3% last Friday (after trading was momentarily suspended) following the positive recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for bimekizumab in the treatment of moderate to severe plaque psoriasis. We are not surprised by this verdict which is more a confirmation of our opinion on its clinical development. To recap, the phase III data (BE SUR...UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.